Ashleigh Furlong
Health Reporter at Bloomberg News
Health reporter @bloomberg. Previously @POLITICOEurope, @ResFortnight and @GroundUp_News. Views my own. Send tips to [email protected] or DM me.
Articles
-
4 days ago |
news.bloomberglaw.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong
Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. The pharmaceutical firm has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.
-
4 days ago |
bloomberglinea.com.br | Phoebe Sedgman |Amber Tong |Ashleigh Furlong |Seong Joon Cho
Bloomberg — A Sanofi concordou em comprar a Blueprint por pelo menos US$ 9,1 bilhões, à medida que a farmacêutica francesa se expande ainda mais em doenças imunológicas raras. A Sanofi pagará US$ 129 por ação pela biotecnologia americana, informou em um comunicado. Isso representa um prêmio de 27% sobre o preço de fechamento da Blueprint na sexta-feira.
-
4 days ago |
news.bloombergtax.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong
Sanofi SA agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker further expands its rare immunological disease portfolio. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. Sanofi has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.
-
4 days ago |
bloomberg.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong
Laboratory research. Photographer: SeongJoon Cho/Bloomberg(Bloomberg) -- Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday.
-
1 week ago |
news.bloombergtax.com | Ashleigh Furlong
XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 4K
- Tweets
- 3K
- DMs Open
- Yes
The pharma industry is flocking to Spain. We wanted to know why. The answer was fascinating: Tax breaks; cheap, good quality science and a government bending over backwards to attract investment. Story W/@clarahenz, @rorihuela, @jhjanicki Gift link: https://t.co/3yNugmwCcF
RT @basteiro: Cómo España se ha convertido en uno de los países favoritos (de todo el mundo) para las farmacéuticas https://t.co/rNj8J8eT1…
RT @AntonySguazzin: Progress in combating HIV/AIDS may be about to reverse as the Trump administration guts funding @ashleighfurlong @janic…